Unlike other anti-cancer therapeutics for neuroblastoma, as shown in Figure 4, didymin could stimulate expression of Raf kinase inhibitory protein (RKIP) and inhibits N-Myc expression, while not involving p53 during the proapoptotic process [56]. Here, MYCN is linked to neuroblastoma.